Parmax Pharma share news, announcements and annual reports
BSE: 540359Pharmaceuticals & BiotechnologySmall Cap
Share price at the BSE close on 26 Oct 2026. Previous close ₹136.40.
26 Oct: open ₹135.05, high ₹135.05, low ₹135.05
- Under BSE's graded surveillance, stage 0, on the list for 29 Oct 2026. The exchange puts a share here when its price has moved unusually, and trading in it carries extra conditions.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹93 Cr4,411th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- Lossover the last 12 months
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- Shares changed
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business.
- Net worth zero or below
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- −70.0%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- Net worth zero or below
- Volume, BSEVolume. Shares traded on the last trading day. Volume in the glossary
- 657
Parmax Pharma share news and announcements
390 announcements, routine notices left out, newest first. Page 6 of 8.
Sep 2020
15 Sep · Outcome Of The Proceedings Of The Meeting Of The Board Of Directors Of The Company
10 Sep · Board meeting
Meeting on 15 Sep 2020: annual general meeting and quarterly results
Aug 2020
25 Aug · Intimation For Temporary Closure Of Company'S Manufacturing Unit.
Jul 2020
28 Jul · Board meeting
Meeting on 31 Jul 2020: audited results21 Jul · Shareholding for the Period Ended June 30, 2020
Shareholding Pattern for the Period Ended June 30, 2020. For more details, kindly Click ....16 Jul · Subject: Update Regarding Production Of Intermediates Of 'Hydroxy Chloroquine'
13 Jul · Statement Of Investor Complaints For The Quarter Ended June 2020
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 1 0 1 0
May 2020
26 May · Certificate Pursuant To Regulation 40(9) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Half Year Ended 31St March, 2020.
Apr 2020
27 Apr · Shareholding for the Period Ended March 31, 2020
Shareholding Pattern for the Period Ended March 31, 2020. For more details, kindly Click ....25 Apr · Update Regarding Production Of Intermediates Of 'Hydroxy Chloroquine'.
17 Apr · Compliance Certificate Pursuant To Regulation 7(3) Of Securities And Exchange Board Of India (Listing Obligations And Disclosures Requirements) Regulations, 2015 For The Year Ended On 31St March, 2020.
9 Apr · Statement Of Investor Complaints For The Quarter Ended March 2020
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0 1 0 1
Feb 2020
12 Feb · Outcome Of The Proceedings Of The Meeting Of The Board Of Directors Of The Company
5 Feb · Board meeting
Meeting on 12 Feb 2020: quarterly results
Jan 2020
18 Jan · Shareholding for the Period Ended December 31, 2019
Shareholding Pattern for the Period Ended December 31, 2019. For more details, kindly Click ....6 Jan · Statement Of Investor Complaints For The Quarter Ended December 2019
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0 0 0 0
Nov 2019
6 Nov · Board meeting
Meeting on 14 Nov 2019: quarterly results
Oct 2019
22 Oct · Shareholding for the Period Ended September 30, 2019
Shareholding Pattern for the Period Ended September 30, 2019. For more details, kindly Click ....17 Oct · Certificate Pursuant To Regulation 40(9) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Half Year Ended 30Th September, 2019.
10 Oct · Compliance Certificate Pursuant To Regulation 7(3) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations,2015 For Half Year Ended On 30Th September, 2019
4 Oct · Statement Of Investor Complaints For The Quarter Ended September 2019
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0 0 0 0
Sep 2019
30 Sep · Results
Details of Voting results of AGM, under Regulation 44(3) of SEBI (LODR) Regulations, 2015. Kindly ....7 Sep · Reg. 34 (1) Annual Report
Aug 2019
2 Aug · Board meeting
Meeting on 9 Aug 2019: quarterly results
Jul 2019
22 Jul · Shareholding for the Period Ended June 30, 2019
Shareholding Pattern for the Period Ended June 30, 2019. For more details, kindly Click ....9 Jul · Statement Of Investor Complaints For The Quarter Ended June 2019
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0 0 0 0
May 2019
23 May · Board meeting
Meeting on 30 May 2019: audited results